文献速递头颈外科

评估两周期铂类联合多西他赛及新型Bcl-xL抑制剂诱导化疗的喉器官保留随机试验

Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor.
PubMed 文献 · Head Neck · 2022-04-13

该II期生物选择试验纳入54例晚期可切除喉癌患者,采用两周期铂类联合多西他赛(TP)加Bcl-2抑制剂的诱导化疗方案,主要终点为化放疗后12周器官保留率。诱导化疗反应率为72%,器官保留率为59%,无喉切除术生存率为46%;诱导相关≥3级毒性发生率为56%,含2例5级事件。结论认为两周期TP诱导化疗加Bcl-2抑制剂与单周期PF方案相比未改善喉保留。

要点

  • 54例晚期可切除喉癌患者接受两周期TP联合Bcl-2抑制剂诱导化疗。
  • 诱导化疗反应率72%,12周器官保留率59%,无喉切除术生存率46%。
  • 诱导相关≥3级毒性发生率56%,包括2例5级事件。

核心结论

  • 两周期TP诱导化疗加Bcl-2抑制剂与单周期PF方案相比未改善喉保留。

研究设计与样本

  • II期生物选择试验,纳入54例晚期可切除喉癌患者。
  • 诱导化疗方案为两周期铂类联合多西他赛(TP)加Bcl-2抑制剂。
  • 主要终点为化放疗后12周器官保留率。

主要发现

  • 诱导化疗反应率为72%。
  • 器官保留率为59%。
  • 无喉切除术生存率为46%。
  • 诱导相关≥3级毒性发生率为56%,含2例5级事件。

关键数值与推荐

  • 原文未报告具体疗效判定标准或推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Single cycle induction chemotherapy (IC) with platinum and 5-flurouracil (PF) and treatment based on clinical response predicts organ preservation in laryngeal cancer. Other agents offer intriguing alternatives with potentially increased ease of administration, reduced risk for severe toxicities, and increased platinum sensitivity. METHODS: We report the results of a phase II bioselection trial in advanced resectable laryngeal cancer utilizing an IC regimen of two cycles of platinum plus docetaxel (TP) with a Bcl-2 inhibitor. The primary endpoint was organ preservation rate at 12 weeks post chemoradiation. RESULTS: Fifty-four patients were enrolled. Response to IC was 72%. The organ preservation rate was 59% with a laryngectomy free survival of 46%. Induction related grade ≥3 toxicities were observed in 56% of patients with two grade 5 events. CONCLUSIONS: Two cycles of TP IC plus a Bcl-2 inhibitor did not improve laryngeal preservation compared to a single cycle of PF.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Swiecicki PL, Bellile E, Casper K, et al. Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor. Head Neck. 2022. PMID: 35416374. doi:10.1002/hed.27043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。